Michael Deininger

Michael Deininger at Medical College of Wisconsin has been a leader in understanding and overcoming imatinib resistance in CML, contributing to the understanding of ABL kinase domain mutations including T315I as resistance mechanisms and the development of second and third-generation TKIs. His research on the molecular monitoring of CML treatment response and the definition of response milestones has shaped treatment guidelines. He has been involved in the DASISION and ENESTnd trials comparing second-generation TKIs to imatinib. His comprehensive clinical and laboratory research on CML management has contributed to the current landscape where most CML patients achieve excellent long-term outcomes.